Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044294 | 0.94 | HCAR3 (0.58) | HCAR3ALDH1A1TSHRLMNAGLA | |
| SCHEMBL6044259 | 0.84 | HCAR3 (0.60) | HCAR3ALDH1A1GRM5RXFP1TSHR | |
| SCHEMBL6043830 | 0.78 | HCAR3 (0.50) | HCAR3ALDH1A1GRM5RXFP1TSHR | |
| SCHEMBL6043674 | 0.78 | HCAR3 (0.58) | HCAR3ALDH1A1RXFP1TSHRLMNA | |
| SCHEMBL6044013 | 0.75 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTGAA | |
| SCHEMBL6044743 | 0.75 | HCAR3 (0.52) | HCAR3ALDH1A1RXFP1TSHRLMNA | |
| SCHEMBL6044728 | 0.73 | HCAR3 (0.53) | HCAR3ALDH1A1GRM5RXFP1TSHR | |
| SCHEMBL6044613 | 0.73 | HCAR3 (0.60) | HCAR3ALDH1A1GRM5RXFP1TP53 | |
| SCHEMBL6044131 | 0.72 | HCAR3 (1.00) | HCAR3RXFP1TP53MAPTGAA | |
| SCHEMBL6044966 | 0.72 | HCAR3 (0.48) | HCAR3ALDH1A1TSHRLMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885ALDH1A1 607/4885GRM5 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.